肿瘤细胞治疗研究
英文原题：Facts and prospects of peptide in targeted therapy and immune regulation against triple-negative breast cancer.
三阴性乳腺癌（TNBC）是乳腺癌中最具侵袭性的亚型。
三阴性乳腺癌（TNBC）是乳腺癌中最具侵袭性的亚型。由于缺乏特异性治疗靶点，治疗选择有限，复发和转移率高，患者总体生存期较差。然而，随着一些新靶点的发现以及靶向这些靶点后相应的免疫调节作用，TNBC的治疗出现了新的希望。多肽结构简单、结合亲和力强、稳定性高，在针对TNBC的靶向治疗和免疫调节方面具有巨大潜力。本综述将讨论单肽和多肽组合如何靶向三阴性乳腺癌以发挥免疫调节作用。其中，单肽靶向TNBC细胞上的特定受体，作为诱饵靶向调节通路中的关键配体，并靶向TME相关细胞。多肽组合以癌症疫苗、工程化外泌体、microRNA及其他免疫相关分子通路、免疫检查点抑制剂、CAR-T 细胞和药物-多肽偶联物的形式发挥作用。本文主要致力于探索TNBC的新治疗方法，以提高疗效并延长患者的生存时间。
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. Due to the lack of specific therapeutic targets, treatment options are limited, and the recurrence and metastasis rate is high, the overall survival of patients is poor. However, with the discovery of some new targets and the corresponding immune regulation after targeting these targets, TNBC has a new hope in treatment. The peptide has a simple structure, strong binding affinity, and high stability, and has great potential in targeted therapy and immune regulation against TNBC. This review will discuss how single peptides and peptide combinations target triple-negative breast cancer to exert immunomodulatory effects. Among them, single peptides target specific receptors on TNBC cells, act as decoys to target key ligands in the regulatory pathway, and target TME-related cells. The combinations of peptides work in the form of cancer vaccines, engineered exosomes, microRNAs and other immune-related molecular pathways, immune checkpoint inhibitors, chimeric antigen receptor T cells, and drug-peptide conjugates. This article is mainly dedicated to exploring new treatment methods for TNBC to improve the curative effect and prolong the survival time of patients.
MEMBER ACCOUNT
登录成功会直接打开下一页。
